Another example, NewLimit, a biotech co-founded by Coinbase CEO Brian Armstrong, has garnered headlines for raising $130 million. From the outset, Kleiner Perkins led the up round’s successful Series B funding round. The significant investment aims to advance NewLimit’s mission to enhance the length of healthy life by genetically programming cells to restore youthful characteristics.
NewLimit was born more than four years ago. Since completing a $40 million Series A funding round two years ago, the company has achieved some incredible milestones. The company is working on the first potentially industry age-reversing treatment using unique methods to rejuvenate old cells. Co-founders Blake Bryers, a former partner at GV, and Jacob Kimmel, a stem cell professor, work alongside Armstrong to lead the initiative.
That latest funding round attracted investments from high-profile individuals and firms. Joining them were firsts, including Nat Friedman, Daniel Gross, and Khosla Ventures, as well as repeat backers Founders Fund, Dimension Capital, Elad Gil, Garry Tan and Patrick Collison. This financial support further bolsters the confidence that investors have in NewLimit’s potential to revolutionize health and longevity.
According to NewLimit, the research behind these datasets is far advanced. Laboratory studies indicate that rejuvenation might be able to return aged cells’ capacity to metabolize fat and alcohol efficiently. These results are an important step forward in the development of new treatments. They have the potential to change what the medical field thinks about aging.
NewLimit’s breakthroughs hold tremendous potential. The company knows it’s got a few more years yet before beginning human trials. The journey to clinical first applications might be long, but NewLimit is excited about its research path and believes it shows great promise.
Blake Bryers stressed the importance of artificial intelligence in their research approach, saying,
“What the AI model allows us to do is run all those experiments in simulation and then only follow up on the most promising subset.” – Blake Bryers
This intelligent fusion of biology and technology is an exciting new frontier in how we study and fight the negative effects of aging.